Microbial Biofilms: Human T-cell Leukemia Virus Type 1 First in Line for Viral Biofilm but Far Behind Bacterial Biofilms

Maali, Yousef; Journo, Chloé; Mahieux, Renaud; Dutartre, Hélène

doi:10.3389/fmicb.2020.02041

Cited by 16 publications

(17 citation statements)

References 153 publications

(191 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the case of fungi, the ECM also provides antifungal resistance by binding to antifungal agents and preventing entry to their deliberate targets at the surface or within fungal cells, other than acting as a protective barrier against chemical and biological agents [ 31 ]. In the case of viruses, ECM is used for adhesion to the target cells followed by interaction with cell surface receptors permitting their entry [ 32 ].…”

Section: Microbial Cell–surface Interactionmentioning

confidence: 99%

Antimicrobial surfaces: a review of synthetic approaches, applicability and outlook

2021

View full text Add to dashboard Cite

The rapid spread of microorganisms such as bacteria, fungi, and viruses can be extremely detrimental and can lead to seasonal epidemics or even pandemic situations. In addition, these microorganisms may bring about fouling of food and essential materials resulting in substantial economic losses. Typically, the microorganisms get transmitted by their attachment and growth on various household and high contact surfaces such as doors, switches, currency. To prevent the rapid spread of microorganisms, it is essential to understand the interaction between various microbes and surfaces which result in their attachment and growth. Such understanding is crucial in the development of antimicrobial surfaces. Here, we have reviewed different approaches to make antimicrobial surfaces and correlated surface properties with antimicrobial activities. This review concentrates on physical and chemical modification of the surfaces to modulate wettability, surface topography, and surface charge to inhibit microbial adhesion, growth, and proliferation. Based on these aspects, antimicrobial surfaces are classified into patterned surfaces, functionalized surfaces, superwettable surfaces, and smart surfaces. We have critically discussed the important findings from systems of developing antimicrobial surfaces along with the limitations of the current research and the gap that needs to be bridged before these approaches are put into practice. Supplementary Information The online version contains supplementary material available at 10.1007/s10853-021-06404-0.

show abstract

Section: Microbial Cell–surface Interactionmentioning

confidence: 99%

Antimicrobial surfaces: a review of synthetic approaches, applicability and outlook

2021

View full text Add to dashboard Cite

show abstract

“…HTLV-1 spread within an infected individual may occur by clonal expansion of infected T cells or by viral transfer via cell-cell contact [ 53 , 54 , 55 ]. In contrast to HIV-1, free virions of HTLV-1 are not efficiently infectious as they are mostly undetectable in plasma, serum, or cell-free blood products [ 54 ].…”

Section: Introductionmentioning

confidence: 99%

“…In contrast to HIV-1, free virions of HTLV-1 are not efficiently infectious as they are mostly undetectable in plasma, serum, or cell-free blood products [ 54 ]. Therefore, the primary modes of viral spread are via virological synapses (VS), viral biofilm (VB), cellular conduits (CC), and tunneling nanotubes (TNTs) [ 54 , 55 , 56 ]. Some of the molecular players that may allow cell-cell contact in HTLV-1 infection are the intercellular adhesion molecule 1 (ICAM-1), lymphocyte function-associated antigen (LFA-1), galectin-3, O-glycosylated surface receptors (CD43 and CD45), viral envelope glycoproteins (gp61/46), viral transactivator Tax, viral protein p8, carbohydrates, and components of the extracellular matrix (collagen, agrin) [ 54 , 56 ].…”

Section: Introductionmentioning

confidence: 99%

Extracellular Vesicles in HTLV-1 Communication: The Story of an Invisible Messenger

Sharif

Pinto

Mensah

et al. 2020

Viruses

View full text Add to dashboard Cite

Human T-cell lymphotropic virus type 1 (HTLV-1) infects 5–10 million people worldwide and is the causative agent of adult T-cell leukemia/lymphoma (ATLL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) as well as other inflammatory diseases. A major concern is that the most majority of individuals with HTLV-1 are asymptomatic carriers and that there is limited global attention by health care officials, setting up potential conditions for increased viral spread. HTLV-1 transmission occurs primarily through sexual intercourse, blood transfusion, intravenous drug usage, and breast feeding. Currently, there is no cure for HTLV-1 infection and only limited treatment options exist, such as class I interferons (IFN) and Zidovudine (AZT), with poor prognosis. Recently, small membrane-bound structures, known as extracellular vesicles (EVs), have received increased attention due to their potential to carry viral cargo (RNA and proteins) in multiple pathogenic infections (i.e., human immunodeficiency virus type I (HIV-1), Zika virus, and HTLV-1). In the case of HTLV-1, EVs isolated from the peripheral blood and cerebral spinal fluid (CSF) of HAM/TSP patients contained the viral transactivator protein Tax. Additionally, EVs derived from HTLV-1-infected cells (HTLV-1 EVs) promote functional effects such as cell aggregation which enhance viral spread. In this review, we present current knowledge surrounding EVs and their potential role as immune-modulating agents in cancer and other infectious diseases such as HTLV-1 and HIV-1. We discuss various features of EVs that make them prime targets for possible vehicles of future diagnostics and therapies.

show abstract

“…Bacterial release from the biofilm requires degradation of biofilm polymers by enzymes and surfactant molecules that reduce surface-bacterial interactions. Although the processes leading to the synthesis, stability, and regulation of bacterial biofilms have been widely studied, the kinetics and dynamics of ECM remodeling mechanisms leading to the formation of viral biofilm have not been investigated yet, but can be drawn from scarce literature data [3].…”

Section: Resultsmentioning

confidence: 99%

BIOFILM AND TUMOR: INTERPRETATION OF INTERACTION AND TREATMENT STRATEGIES. Review

Ivanenko

2021

Med. Sci. of Ukr.

View full text Add to dashboard Cite

Relevance. Treatment of solid tumors and biofilm-derived infections face a common problem: drugs often fail to reach and kill cancer cells and microbial pathogens because of local microenvironment heterogeneities. There are remarkable challenges for current and prospective anticancer and antibiofilm agents to target and maintain activity in the microenvironments where cancer cells and microbial pathogens survive and cause the onset of disease. Bacterial infections in cancer formation will increase in the coming years. Collection of approaches such as ROS modulation in cells, the tumor is promoted by microbe’s inflammation can be a strategy to target cancer and bacteria. Besides that, bacteria may take the advantage of oxygen tension and permissive carbon sources, therefore the tumor microenvironment (TM) becomes a potential refuge for bacteria. It is noteworthy that the relationship between cancer and bacteria is intertwined. Objective: To analyze similarities between biofilm and tumor milieu that is produced against stress conditions and heterogeneous microenvironment for a combination of approaches the bacteriotherapy with chemotherapy which can help in defeating the tumor heterogeneity accompanied with malignancy, drug-resistance, and metastasis. Method: An analytical review of the literature on keywords from the scientometric databases PubMed, Wiley. Results: Bacteria evade antimicrobial treatment is mainly due to persistence that has become dormant during the stationary phase and tolerance. Drug-tolerant persisters and cellular dormancy are crucial in the development of cancer, especially in understanding the development of metastases as a late relapse. Bioﬁlms are formed by groups of cells in diﬀerent states, growing or non-growing and metabolically active or inactive in variable fractions, depending on maturity and on chemical gradients (O2 and nutrients) of the bioﬁlms producing physiological heterogeneity. Heterogeneity in the microenvironment of cancer can be described as a non-cell autonomous driver of cancer cell diversity; in a highly diverse microenvironment, different cellular phenotypes may be selected for or against in different regions of the tumor. Hypoxia, oxidative stress, and inflammation have been identified as positive regulators of metastatic potential, drug resistance, and tumorigenic properties in cancer. It is proven that, Escherichia coli (E. coli) and life-threatening infectious pathogens such as Staphylococcus aureus (SA) and Mycobacterium tuberculosis (Mtb) are noticeably sensitive to alterations in the intracellular oxidative environment. An alternative emerging paradigm is that many cancers may be promoted by commensal microbiota, either by translocation and adherence of microbes to cancer cells or by the distant release of inflammation-activating microbial metabolites. Microbial factors such as F. nucleatum, B. fragilis, and Enterobacteriaceae members may contribute to disease onset in patients with a hereditary form of colorectal cancer (CRC); familial adenomatous polyposis (FAP). These findings are linked with the creation of new biomarkers and therapy for identifying and treating biofilm-associated cancers. Currently, about 20% of neoplasms globally can be caused by infections, with approximately 1.2 million cases annually. Several antineoplastic drugs that exhibited activity against S. mutans, including tamoxifen, doxorubicin, and ponatinib, also possessed activity against other Gram-positive bacteria. Drug repurposing, also known as repositioning, has gained momentum, mostly due to its advantages over de novo drug discovery, including reduced risk to patients due to previously documented clinical trials, lower drug development costs, and faster benchtop-to-clinic transition. Although many bacteria are carcinogens and tumor promoters, some have shown great potential towards cancer therapy. Several species of bacteria have shown an impressive power to penetrate and colonize solid tumors, which has mainly led to neoplasm slower growth and tumor clearance. Different strains of Clostridia, Lactococcus, Bifidobacteria, Shigella, Vibrio, Listeria, Escherichia, and Salmonella have been evaluated against cancer in animal models. Conclusion. Cancer is a multifactorial disease and the use of bacteria for cancer therapy as an immunostimulatory agent or as a vector for carrying the therapeutic cargo is a promising treatment method. Therefore, the world has turned to an alternative solution, which is the use of genetically engineered microorganisms; thus, the use of living bacteria targeting cancerous cells is the unique option to overcome these challenges. Bacterial therapies, whether used alone or combination with chemotherapy, give a positive effect to treat multiple conditions of cancer.

show abstract

Microbial Biofilms: Human T-cell Leukemia Virus Type 1 First in Line for Viral Biofilm but Far Behind Bacterial Biofilms

Cited by 16 publications

References 153 publications

Antimicrobial surfaces: a review of synthetic approaches, applicability and outlook

Antimicrobial surfaces: a review of synthetic approaches, applicability and outlook

Extracellular Vesicles in HTLV-1 Communication: The Story of an Invisible Messenger

BIOFILM AND TUMOR: INTERPRETATION OF INTERACTION AND TREATMENT STRATEGIES. Review

Contact Info

Product

Resources

About